Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD‐1/PDL‐1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer

Immune checkpoint blockade (ICB) is an approved therapy for advanced metastatic mismatch repair (MMR)‐deficient cancer regardless of tissue of origin. Although therapy is effective initially, recurrence rates are significant, and long‐term outcomes remain poor for most patients. It is not currently...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncologist
Main Authors: Winer, Arthur, Ghatalia, Pooja, Bubes, Nicole, Anari, Fern, Varshavsky, Asya, Kasireddy, Vineela, Liu, Yang, El‐Deiry, Wafik S.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Inc. 2019
Fag:
Precision Medicine Clinic: Molecular Tumor Boards
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853126/
https://ncbi.nlm.nih.gov/pubmed/31444293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0686
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker